Merck & Co.’s first-in-class HIF-2 alpha inhibitor Welireg is touching down in the clear cell renal cell carcinoma (ccRCC) | ...

The approvals are based on data from the pivotal Phase III LITESPARK-022 trial, which enrolled 1,841 patients.

Merck (MRK) stock is in focus as the FDA approves a label expansion for the company's kidney cancer drug Welireg with its ...

For 2029, a federal rule proposes closing a "loophole" that protects medicines transitioning from intravenous administration ...

Merck’s MRK strong foothold in the oncology space is propelled by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounted for more than 50% of the company’s ...

In early June 2026, Gilead Sciences and Merck reported that their investigational once-weekly oral HIV regimen of ...

Merck MRK boasts more than six blockbuster drugs in its portfolio, with the blockbuster PD-L1 inhibitor Keytruda being the key top-line driver. Keytruda, approved for several types of cancer, alone ...

Merck looks like a buy-the-dip at $114.90 with a 3% yield and 12x forward P/E. Click here to read more on the MRK stock.

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. But the breakthrough approval comes ...